Neonates <7 days: Most pre-term neonates <
7 days of age (gestational age < 34 weeks) have lower systemic linezolid
clearance values and larger AUC values than many full-term neonates and
older infants. These neonates should be initiated with a dosing regimen
of 10 mg/kg q12h. Consideration may be given to the use of 10 mg/kg q8h
regimen in neonates with a sub-optimal clinical response. All neonatal
patients should receive 10 mg/kg q8h by 7 days of life.
Oral dosing: Use either ZYVOX Tablets or ZYVOX for Oral Suspension
Adult patients with infection due to MRSA should be treated
with ZYVOX 600 mg q12h.
In limited clinical experience, 5 out of 6 (83%) pediatric patients with
infections due to Gram-positive pathogens with MICs of 4 µg/mL treated with
ZYVOX had clinical cures. However, pediatric patients exhibit wider variability
in linezolid clearance and systemic exposure (AUC) compared with adults. In
pediatric patients with a sub-optimal clinical response, particularly those with
pathogens with MIC of 4 µg/mL, lower systemic exposure, site and severity of
infection, and the underlying medical condition should be considered when
assessing clinical response.
In controlled clinical trials, the protocol-defined duration of treatment for
all infections ranged from 7 to 28 days. Total treatment duration was determined
by the treating physician based on site and severity of the infection, and on
the patient's clinical response.
No dose adjustment is necessary when switching from intravenous to oral
administration. Patients whose therapy is started with ZYVOX I.V. Injection may
be switched to either ZYVOX Tablets or Oral Suspension at the discretion of the
physician, when clinically indicated.
Renal: no adjustment necessary.
(Two primary metabolites of linezolid may accumulate in patients with
renal insufficiency- more studies are needed to determine the clinical
No adjustment necessary. On dialysis days, schedule dose after
dialysis. (~30% extraction).
The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical
judgment. Neither GlobalRPh Inc. nor any other party involved in the
preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material.PLEASE READ THE DISCLAIMER
BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU
AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Read